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Background: The life cycle of Plasmodium is complex, requiring invasion of two different hosts, humans and
mosquitoes. In humans, initiation of an effective Th1 response during early infection is critical for the control of
parasite multiplication. In mosquitoes, inhibition of the development of sexual-stage parasites interrupts the parasite
transmission. In this study, we aim to investigate whether dietary supplementation of L-arginine (L-Arg) in mice affects
Plasmodium yoelii 17XL (Py17XL) transmission in mosquitoes.
Methods: BALB/c mice were orally administered with 1.5 mg/g L-Arg daily for 7 days and infected with Py17XL. The
mRNA levels of inducible nitric oxide synthase (iNOS) and arginase 1 in spleen cells were determined by real-time RT-PCR.
The amount of nitric oxide (NO) released by spleen cells in vitro was determined by the Griess method. The effect of
L-Arg supplementation on subsequent development of P. yoelii gametocytes was evaluated by an in vitro ookinete
culture assay and mosquito feeding assay.
Results: Pretreatment of mice with L-Arg significantly increased the transcript level of iNOS in spleen cells and
the amount of NO synthesized. Dietary L-Arg supplementation also significantly reduced the number of zygotes
and ookinetes formed during in vitro culture and the number of oocysts formed on mosquito midguts after
blood feeding.
Conclusions: L-Arg enhances host immunity against blood-stage parasites as well as suppressing subsequent
parasite development in mosquitoes. L-Arg as an inexpensive and safe supplement may be used as a novel adjunct
treatment against malarial infection.
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Malaria is a serious vector-borne disease that accounts for
over half a million deaths annually. This infection not only
remains widespread throughout the tropics, but also oc-
curs in many temperate regions [1]. The intolerable health
burden of malaria and its socio-economic impacts have in-
spired the development of a Global Malaria Action Plan
by the World Health Organization (WHO) [2], which has
re-established elimination and eradication on the malaria
control agenda.* Correspondence: ymcao@mail.cmu.edu.cn
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creativecommons.org/publicdomain/zero/1.0/The life cycle of Plasmodium is complex. Usually,
people get malaria after being bitten by an infected fe-
male Anopheles mosquito. The parasites first multiply in
the human liver and subsequently infect red blood cells.
All symptoms of malaria including fever, anaemia, and
neurological pathology, appear during the blood stages
of the infection. Therefore, medications are primarily
directed against the blood-stage parasites to ameliorate
the malaria symptoms, whereas transmission blocking
strategies target the sexual stages such as gametocyte,
zygote, and ookinete [3, 4].
L-Arginine (L-Arg), an essential amino acid in newborns
and infants, is the sole substrate of nitric oxide (NO) syn-
thase required for the production of NO. Hypoarginine-
mia can lead to impaired systemic NO production [5].ticle distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
Zheng et al. Parasites & Vectors  (2015) 8:326 Page 2 of 6Therefore, effects of L-Arg supplementation are mostly
likely due to functional enhancement of iNOS activity [6].
Low arginine, low nitric oxide production, and endothelial
dysfunction are common in severe malaria [7]. In patients
with severe malaria, supplementation with L-Arg has been
shown to improve NO bioavailability and reverse endothe-
lial dysfunction [8]. We have recently shown that supple-
mentation of L-Arg promotes the maturation of dendritic
cells and improves protective immunity during early-stage
Plasmodium yoelii 17XL (Py17XL) infection [9]. We have
also shown that exogenous NO inhibits the development
of P. yoelii gametocytes into gametes [10]. Direct supple-
mentation of NO is not feasible, as NO is a short-lived free
radical and direct NO administration has severe side effects
for the host. In contrast, L-Arg is a safe and widely ac-
cepted amino acid supplement that has been used in
humans for decades [11].
In this study, we studied the effects of L-Arg supplemen-
tation on the transcript levels of two arginine-metabolizing
enzymes nitric oxide synthase (iNOS) and arginase 1
(ARG1). We then determined the effects of L-Arg sup-
plementation on NO production in splenocyte culture
and the development of zygotes and ookinetes in vitro
and the formation of oocysts in vivo. Our results confirmed
that L-Arg supplementation in mice enhances the expres-
sion of iNOS and further inhibits the development of sexual
stages in mosquitoes.
Methods
Mice, parasite, infection, and L-Arg treatment
Female BALB/c mice (6–8 weeks of age) were purchased
from the Center of Zoology, Chinese Academy of Sciences.
Infections with Py17XL were initiated by intraperito-
neal injection of 106 Py17XL parasitized erythrocytes
per mouse. Parasitemia was monitored by light microscopy
of Giemsa-stained thin blood smears. Mortality was moni-
tored daily. All experiments were performed in compliance
with regulations of the animal ethics committee of China
Medical University.
L-Arg (Sigma-Aldrich, St. Louis, MO, USA) was dis-
solved in normal saline prior to use. Mice were admin-
istered an oral dose of 1.5 mg/g L-Arg daily for seven
consecutive days prior to infection with Py17XL. The
control group received D-Arg dissolved in the same
volume of normal saline at identical time points.
Splenocyte preparation and culture
Splenocyte culture was prepared as previously described
[12]. Splenocytes were adjusted to a final density of 107
cells/mL in RPMI-1640 supplemented with 10 % heat-
inactivated fetal calf serum, seeded in 24-well flat-bottom
Falcon tissue culture plates (Corning, Tewksbury, MA,
USA) in triplicate at 5 × 106/well, and incubated at 37 °C
for 48 h in a humidified 5 % CO2 incubator. The resultingsupernatants were collected and stored at −80 °C for
quantification of NO levels.
RNA extraction and real-time RT-PCR
Total RNA was isolated from spleen cells using TRIzol®.
The ratios of absorbance at 260/280 nm ranged from
1.80 to 2.00 for all RNA samples. Total RNA was stored
at −70 °C. cDNA was synthesized using the PrimeScriptTM
RT reagent kit with gDNA Eraser (Takara, Japan). Reverse
transcription was performed in a 10 μL reaction mixture
containing PrimeScriptTM buffer, PrimeScriptTM RT en-
zyme mix, oligo dT primer (50 μM), random hexamers
(100 μM), and 500 ng total RNA. PCR was performed
using the resulting cDNA as a template and gene-specific
primers. Primers used for PCR were as follows: iNOS
forward (5′ TCCTCACTGG GACAGCACAGAATG 3′)
and reverse (5′ GTGTCATGCAAAATCTCTCCACTGCC
3′); and ARG1 forward (5′ ATGGAAGAGACCTTCAGC
TAC 3′) and reverse (5′ GCTGTCTTCCCAAGAGTTGG
G 3′). Quantitative PCR was carried out using the SYBR®
Premix Ex Taq™ reagent kit (Takara) in an AB7500 in-
strument (Applied Biosystems, USA). After denaturation at
95 °C for 30 s, 40 cycles of 95 °C for 5 s, followed by 60 °C
for 30 s were performed. β-actin was used as an internal
control with forward primer (5′ GATTACTGCTCTGGCT
CCTAGC 3′) and reverse primer (5′ GACTCATCGTACT
CCTGCTTGC 3′). Each experiment was performed three
times independently. The average cycle threshold of the du-
plicate measurements was calculated. The 2-ΔΔCT method
was used to quantify the relative gene expression in the L-
Arg treatment group compared with the control group
[13]. All quantitative PCR procedures, including primer de-
sign, validation of the PCR environment, and quantification
were performed according to the Minimum Information
for Publication of Quantitative Real-Time PCR Experiment
guidelines [14].
Determination of nitrite (NO2
−) concentrations
Concentrations of NO2
− from the supernatants of spleno-
cyte culture were measured using the Griess reaction [10].
Briefly, 100 μL of each supernatant was incubated with
100 μL of Griess reagent for 10 min at room temperature.
NO2
− concentration was determined by measuring the op-
tical density at 550 nm (A550) and comparing these values
to the standard curve of NaNO2 solution.
Measurement of intracellular reactive oxidant species
(ROS) in spleen cells
ROS quantification was performed by measuring the
oxidative conversion of 2,7-dichlorodihydrofluorescein
diacetate (DCFH-DA) by peroxide. Briefly, 106 splenocytes
were incubated with DCFH-DA for 20 min, after which
2,7-dichlorofluorescein (DCF) fluorescence was detected by
flow cytometry with an excitation wavelength of 488 nm
Fig. 1 Effects of L-Arg treatment iNOS (a) and ARG1 (b). The relative
abundance of iNOS and ARG1 in spleen cells were measured by
quantitative real-time RT-PCR. Spleen cells were collected from mice
prior to Py17XL infection (0), and 3 and 5 dpi. Results are representative
of three independent experiments. For each experiment, three mice
were used per group. Values represent the mean + SEM.* and ** indicate
significant difference between Py17XL infected (3 d and 5 d) and
uninfected mice (0 d) at P < 0.01 and P <0.05 (t-test), respectively.
# and ## indicate significant difference between D-Arg pretreated
control (Normal infection) and L-Arg pretreated mice (L-Arg treatment)
at P < 0.01 and P <0.05 (t-test), respectively
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were repeated in triplicate. The resulting data were
processed with CellQuest (BD Biosciences, San Diego,
CA, USA).
In vitro zygote and ookinete development assay
P. yoelii zygotes and ookinetes were examined using the
24 h ookinete culture assay [15]. Briefly, blood was har-
vested from mice at 3 days post-infection, with the D-Arg
treatment group serving as the control. Ten μl of each
blood sample were combined with 90 μl of ookinete culture
medium and incubated for 24 h at 24 °C. After centrifuga-
tion of the culture, the pellet was resuspended in 50 μL
phosphate-buffered saline (PBS), and 1 μl aliquots were
spotted onto glass slides (Matsunami glass IND., LTD,
Osaka, Japan), air-dried, and fixed with ice-cold acetone.
Zygotes and ookinetes were detected by indirect immuno-
fluorescence assay (IFA) with anti-Pys25 antibody. Slides
were first blocked with PBS containing 5 % non-fat dry
milk for 30 min at 37 °C and then incubated with a
monoclonal anti-Pys25 antibody (1:200) for 60 min. After
rinsing with PBS, the slides were incubated with fluores-
cein isothiocyanate (FITC)-conjugated goat anti-mouse
IgG antibodies (Tago; Camarillo, CA) for 30 min at 37 °C.
After rinsing with PBS, the slides were mounted under a
cover slip in bicarbonate-buffered glycerin, and observed
under a fluorescence microscope. The total numbers of
zygotes and retort ookinetes formed per microlitre of the
aliquots were counted.
Mosquito rearing and infection with P. yoelii
Anopheles stephensi mosquitoes were maintained at 24 °C
and 75 % humidity with a 12 h light/dark cycle. Adult
mosquitoes were kept on a 5 % sucrose solution. Mosqui-
toes were starved overnight prior to experiments and were
allowed to feed on infected mice for 30 min on day 3 post
Py17XL infection. Engorged mosquitoes were isolated,
maintained at 24 °C, fed on 5 % sucrose solution, and
dissected for oocysts 9 days after the blood meal.
Statistical analysis
Statistical significance of differences was determined using
the Student’s t-test and Mann–Whitney U-test. P-values
less than 0.05 were considered significant.
Results
Levels of iNOS and ARG1 transcription
Consistent with our previous finding [9], L-Arg supple-
ment significantly reduced the parasitemia at 5 and 7 dpi,
and significantly prolonged the survival of Py17XL-in-
fected mice (data not shown). The expression of iNOS and
ARG1 in the spleens of uninfected and P. yoelii-infected
mice was determined using quantitative RT-PCR (Fig. 1).
Compared to uninfected mice, Py17XL infection resultedin a significant increase of iNOS transcript at 3 and 5 days
post infection (dpi) (Fig. 1a, P < 0.01, t-test). L-Arg pre-
treatment significantly increased the iNOS transcript
levels compared with the D-Arg pretreated group (Fig. 1a,
P < 0.01). In parallel, compared with the uninfected group,
the control P. yoelii-infected group also showed higher
levels of the ARG1 transcript (Fig. 1b, P < 0.05). However,
L-Arg pretreatment led to a significant decrease of the
ARG1 transcript compared to the untreated control group
(Fig. 1b, P < 0.05), resulting in a similar level of ARG1
mRNA as in the uninfected group.
Levels of NO and ROS
We measured NO production in the culture superna-
tants of spleen cells isolated from L-Arg pretreated and
control mice. The levels of NO2
− gradually increased
from 3 to 5 dpi (Fig. 2a, P < 0.05). The L-Arg pretreat-
ment group produced significantly higher amounts of
NO than the control group (P < 0.05). Similarly, ROS
Fig. 2 Effects of L-Arg treatment on NO (a) and ROS (b) production
in spleen cells. a Supernatants were prepared from splenocyte cultures,
and concentrations of NO2
− were detected using the Griess reaction.
b ROS production was measured by flow cytometry. Spleen cells were
collected from mice prior to Py17XL infection (0 d), and 3 and 5 dpi.
Results are representative of three independent experiments. For each
experiment, three mice were used per group. Values represent the
mean + SEM. * indicates significant difference (P < 0.05, t-test) between
Py17XL infected (3 d and 5 d) and uninfected mice (0 d). # indicates
significant difference (P < 0.05, t-test) between D-Arg pretreated control
(Normal infection) and L-Arg pretreated mice (L-Arg treatment)
Table 1 L-Arg pretreatment inhibits formation of zygotes and
ookinetes




Normal infection 65.5 ± 6.4 20.0 ± 2.8
L-Arg pretreatment 5.0 ± 4.2## 2.5 ± 2.1#
Note: # and ## indicate significant difference between D-Arg pretreated control
(Normal infection) and L-Arg pretreated mice (L-Arg treatment) at P < 0.05 and
P <0.01 (t-test), respectively
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ROS levels in the L-Arg group were lower than that in
the control infected group, although the difference was
only statistically significant at 3 dpi (Fig. 2b, P < 0.05).
Effects of L-Arg on parasite transmission
In addition we compared the transmission-blocking effects
of L-Arg pretreatment in mice infected with Py17XL. At 3
dpi, infected blood was used for in vitro culture of zygotes
and ookinetes and infected mice were used for mosquito
feeding. The numbers of zygotes and ookinetes formed
were significantly reduced in the L-Arg pretreated group
compared to the control group (Table 1, P < 0.05). Simi-
larly, oocyst density was reduced by 89.1 % in mosquitoes
fed on L-Arg pretreated BALB/c mice compared to un-
treated control mice (Fig. 3).
Discussion
NO, produced endogenously through the action of NOS
on its substrate L-Arg, plays a critical role in defending
against infections. At low concentrations, NO acts as a
signaling molecule to enhance the functions of the immune
cells, while at high concentrations, NO directly inhibits or
kills the pathogens. During malaria infection, supplementa-
tion of L-Arg has been shown to improve the protective
immunity during early-stage Py17XL infection [9]. Here we
show that L-Arg supplementation not only enhances the
protective immunity against blood stage malaria parasites,
but also has a transmission-blocking effect.
Resistance to blood-stage malaria infections depends
on the ability of the host to mount an early effective Th1
immune response in order to control parasite growth [16].
This response is predominantly characterized by IFN-γFig. 3 Effects of L-Arg on the infection of A. stephensi by P. yoelii. In
each treatment, 20–30 mosquitoes were dissected and the number
of oocysts per midgut was determined (median and interquartile
range). * indicates significant difference (P < 0.05, Mann–Whitney U-test)
between D-Arg pretreated control (Normal infection) and L-Arg
pretreated mice (L-Arg treatment)
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and activation of monocytes and macrophages are essential
for this process [18, 19]. During phagocytosis, macrophages
generate highly toxic reactive ROS and reactive nitrogen
species (RNS), which damage intracellular components. In
this heightened immune state, addition of L-Arg further en-
hances the Th1 response [9]. This effect is linked to the sig-
nificantly increased expression of iNOS and elevated NO
production in splenocytes. In contrast, though ARG1 tran-
scription was also induced during parasite infection, L-Arg
pretreatment suppressed ARG1 expression. As L-Arg pre-
treatment did not lead to enhanced ROS production in
macrophages, the RNS pathway may play a more important
role in parasite clearance.
We have shown that increased NO production inhibits
asexual parasite growth in infected mice, which may be
partially due to improved host immunity [9] and reduced
expression of parasite invasion molecules such as the apical
membrane antigen 1 (AMA1) [20]. Through the injection
of an L-Arg analog, it was shown that the reduced gam-
etocyte infectivity to mosquitoes during P. yoelii nigeriensis
infection was due to reactive nitrogen intermediates [21].
In this study, we showed that L-Arg supplementation was
detrimental to the sexual stages of the malaria parasites,
resulting in decreased formation of zygotes and ookinetes
in vitro and oocysts in vivo. This result is consistent with
our earlier in vitro study of the effect of NO on gameto-
cytes, suggesting that the L-Arg supplementation effect is
likely due to enhanced NO production of the immune cells.
Taken together, L-Arg supplement, as an inexpensive and
safe supplement, not only promotes the protective immun-
ity against asexual-stage malaria parasites, but also has
transmission-blocking activity, which could be employed to
interrupt the malaria transmission cycle. It is noteworthy
that L-Arg supplement does not improve the outcome of
experimental cerebral malaria in rodents [22], but signifi-
cantly reverses endothelial dysfunction in human malaria
[8], suggesting some differences exist in the two systems.
Therefore, further investigations are needed to determine
the effect of L-Arg on transmission blocking during human
malaria.Conclusions
L-Arg pretreatment could enhance host immunity against
blood-stage malaria parasites and inhibit sexual develop-
ment of parasites in mosquitoes. These effects are likely
due to increased transcription of iNOS and production of
NO. These findings suggest that L-Arg as an inexpensive
and safe supplement may represent a novel adjunct treat-
ment against malarial infection.Competing interests
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